Analysis Vistin Pharma ASA (0RAM)
6/5/2024
Analysis of Vistin Pharma ASA (0RAM)
Vistin Pharma ASA, trading under the symbol 0RAM, has shown a consistent increase in the closing price over the past few weeks. The Relative Strength Index (RSI) indicator has been indicating overbought conditions, with values above 70, suggesting a possible reversal in the short term.The Moving Average Convergence Divergence (MACD) indicator has been positive, but the MACD histogram has been decreasing, indicating a potential weakening of the bullish momentum. The Moving Average (MA) indicator has been steadily increasing, with the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) all showing an upward trend.
Overall, while the stock has been performing well and showing bullish signals, investors should be cautious of the overbought conditions and the potential for a short-term reversal. It would be advisable to monitor the stock closely for any signs of a trend change.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results from February 27, 2025, were related to the Transfer Agent. The results from January 31, 2025, were reported After Hours. The results from October 31, 2024, were not provided at a specific time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 31, 2024. The company shows good returns on assets and equity.
In terms of stock statistics, there is a low short ratio and a significant percentage of shares held by institutions. The stock has a beta of 1.264 and has been trading within a range between a fifty-two-week low and high.
Valuation metrics show a relatively high PEG ratio and forward PE ratio. The company's market capitalization and enterprise value are substantial, with high price to book and price to sales ratios. The enterprise value to EBITDA and revenue ratios are also notable.
The stock price summary includes moving averages, fifty-two-week low and high prices, and the percentage change over the past year.
Lastly, dividends and splits information shows dividend rates, yields, payout ratios, and details about past splits.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. The operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. The net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. The company has been able to maintain a healthy EBITDA margin, which has increased from $81 billion in 2020 to $129.2 billion in 2023.
7. The company's tax expenses have also increased in line with the growth in revenue and income.
8. The basic and diluted earnings per share (EPS) have shown an upward trend, indicating growth in profitability per share.
9. Overall, the financial performance of the company in terms of revenue and income has been positive and shows a healthy growth trajectory.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance/payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities seem to be dynamic, with fluctuations in cash flow and cash position over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows growth compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This indicates an increase from the EPS of $1.35 from the same quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous fiscal year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a potential increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates indicate a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the previous year's same quarter. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the analysts are forecasting moderate to strong sales growth for both the upcoming quarters and the next fiscal year, with the highest growth expected in the next fiscal year ending in September 2025.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is expected to experience steady growth in the short term and moderate growth in the long term according to analyst consensus.
Price target
The analysts' forecast for the future price of the security paper is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security paper, with a median forecast above the current price. However, there is a wide range of estimates, from a low of $164 to a high of $275, indicating some uncertainty in the predictions.
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
